# A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT01181245** · PHASE1 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** FG-3019

## Key facts

- **NCT ID:** NCT01181245
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181245, "A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01181245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*